117324-05-7

Basic information

• Product Name: ETHYL 2-AMINO-4-FLUOROBENZOATE
• Synonyms: ETHYL 2-AMINO-4-FLUOROBENZOATE
• CAS NO: 117324-05-7
• Molecular Formula: C₉H₁₀FNO₂
• Molecular Weight: 183.18
• Product Categories: Esters;Phenyls & Phenyl-Het;Phenyls & Phenyl-Het
• Mol File: 117324-05-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 271.243 °C at 760 mmHg
• Flash Point: 117.844 °C
• Appearance: /
• Density: 1.219 g/cm³
• Vapor Pressure: 0.007mmHg at 25°C
• Refractive Index: 1.536
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.46±0.10(Predicted)
• CAS DataBase Reference: ETHYL 2-AMINO-4-FLUOROBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-AMINO-4-FLUOROBENZOATE(117324-05-7)
• EPA Substance Registry System: ETHYL 2-AMINO-4-FLUOROBENZOATE(117324-05-7)

Safety Data

• Hazardous Substances Data: 117324-05-7(Hazardous Substances Data)

Usage

General Description

ETHYL 2-AMINO-4-FLUOROBENZOATE, also known as ethyl 2-amino-4-fluorobenzoate, is a chemical compound with the molecular formula C9H10FNO2. It is a white to off-white solid that is mainly used as an intermediate for the synthesis of pharmaceuticals and agrochemicals. ETHYL 2-AMINO-4-FLUOROBENZOATE is known for its potential as an anti-inflammatory and analgesic agent, and its structure includes an amino group and a fluorine atom. It is important to handle ethyl 2-amino-4-fluorobenzoate with care, as it may cause skin and eye irritation and is harmful if ingested or inhaled.

InChI:InChI=1/C9H10FNO2/c1-2-13-9(12)7-4-3-6(10)5-8(7)11/h3-5H,2,11H2,1H3

Upstream product

• 446-32-2 4-fluoroanthranilic acid 
• 394-27-4 2-acetamido-4-fluorobenzoic acid 
• 64-17-5 ethanol 

Downstream Products

• 16499-57-3 7-fluoro-3H-quinazolin-4-one 
• 1038343-02-0 C₁₇H₁₆FNO₃ 
• 1038343-01-9 C₁₆H₁₃ClFNO₃ 
• 473416-60-3 2-acetylamino-4-fluorobenzoic acid ethyl ester 
• 196194-86-2 7-(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one 
• 199327-54-3 4-chloro-7-(2-methoxyethoxy)quinazoline 
• 1009368-27-7 2-(2-amino-4-fluorophenyl)propan-2-ol 

Relevant articles and documents

PLATELET ADP RECEPTOR INHIBITORS

no abstract published

Platelet ADP receptor inhibitors

Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.

Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family

We have previously found that the 4-[4-(N-substituted carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazolines can function as potent and selective inhibitors of platelet-derived growth factor receptor (PDGFR) phosphorylation. A series of highly potent, specific, orally active, small molecule kinase inhibitors directed against members of PDGFR receptor have been developed through modifications of the novel quinazoline template I. Systematic modifications in the A-bicyclic ring and D-rings of protype I were carried out to afford potent analogues, which display IC50 values of 50 values of 50-200 nM, whereas 15-20-fold less potent activity against CSF1R was observed. This analogue also inhibits autophosphorylation of Flt-3 ligand-stimulated wild-type Flt-3 and a constitutively activated Flt-3/internal tandem duplication (ITD) with IC50 values of 30-100 nM. Through this optimization process, 75 was found to be metabolically stable and has desirable pharmacokinetic properties in all animal species studied (F% > 50%, T1/2 > 8 h). Oral administration of 75 promotes mice survival and significantly delayed disease progression in a Flt-3/ITD-mediated leukemia mouse model and shows efficacy in a nude mouse model of chronic myelomonocytic leukemia.